39 / 42
Pain Management 2018
Internal Medicine 2018
International Journal of Anesthesiology & Pain Medicine
ISSN: 2471-982X
Page 90
March 26-28, 2018
Vienna, Austria
JOINT EVENT
7
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Internal Medicine and Patient Care
&
6
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Pain Management
Volume 4
Introduction:
Osteoarthritis (OA) is considered the leading cause
of musculoskeletal disability in the elderly population worldwide.
Several studies have shown a potential role of statins as an
alternative treatment option for OA, beyond their cholesterol-
lowering properties. Topical application of atorvastatin had proved
to inducemore anti-inflammatory and hypocholesterolemic effect
in rats with OA as compared to other used anti-inflammatory
drugs such as diclofenac. Therefore, atorvastatin was prepared in
a topical-gel form to be compatible for human use.
Methods:
The study was held at the Rheumatology and
Rehabilitation Department in Mansoura University Hospitals.
Sixty patients with chronic knee OAwere involved in a randomized
controlled trial for a period of 12 months. Each patient underwent
full history taking, full clinical examination, necessary laboratory
investigations, and radiological investigations. The patients were
divided equally into 3 groups of each receiving different drug
regimen as follows: group 1 was the control group receiving the
ordinary regimen provided by the department staff members
(piascledine 300 mg tablet once/day + diclofenac sodium 75 mg
tablet twice/day); group 2 (atorvastatin gel 5% + diclofenac) and
group 3 (atorvastatin gel + diclofenac + glucosamine)
Results:
All patients underwent a clinical assessment via
Western Ontario and McMaster Universities Arthritis index
(WOMAC) twice during the whole period of study; pretreatment
and 12 months post treatment. The collected data were coded,
processed and analyzed using SPSS program. P values less
than 0.05 were considered statistically significant. Group 1
showed a minimal stiffness reduction with an average score of
0.9 pretreatment down to 0.79 post treatment, whereas group 2
showeda significant reduction in theWOMAC index from0.92pre-
treatment to 0.44 post treatment. However, adding glucosamine
to group 3 didn’t prove to improve the patients’ scores as expected
compared to results obtained from group 2 with a reduction from
0.86 to only 0.53, which contributed to about 38.3% of stiffness
reduction as compared to basal level. Whereas group 2 showed a
major improvement in the patients’ WOMAC index in the form of
approx. 52.1% stiffness reduction along the 12 months period of
supervised drug regimen.
Conclusion:
The results obtained by the use of topical
atorvastatin showed to super pass some commercially widely
used chondroprotective agents. Topical atorvastatin may be used
safely and effectively for patients with knee OA.
dr.elkasabi@hotmail.comTopical atorvastatin as a possible chondro-protective
agent in patients with knee osteoarthritis
Mohamed A Elkasabi
Mansoura University, Egypt
Int J Anesth Pain Med 2018, Volume 4
DOI: 10.21767/2471-982X-C1-003